Deutsche Bank Reiterates Buy Rating On CVD And ICLR


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Deutsche Bank is reiterating its Buy rating on shares of Covance Inc. (NYSE: CVD) and ICON plc (NASDAQ: ICLR).“Key takeaways from the Annual Partnerships in Clinical Trials Conference: 1) Vendor consolidation amongst biopharma clients (from 10-to-15 to 2-to-4) and momentum towards strategic deals continues to accelerate,” Deutsche Bank writes.“2) Emerging markets and increased penetration of R&D to drive industry growth. 3) Impact on OMs from pricing discounts to be largely offset by efficiency gains. Given our thesis, we reiterate our Buy rating of CVD (best leverage to strategic deals) and ICLR (GARP).”ICON closed Monday at $21.48; Covance closed at $57.46.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst RatingscovanceDeutsche BankHealth CareICONLife Sciences Tools & Services